[go: up one dir, main page]

IS6009A - Lyfjablöndur sem samanstanda af (E)-7-[4-(4 flúorófenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimidín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýruog lata, vaka eða hvarfefni af P450 ísóensími 3A4 - Google Patents

Lyfjablöndur sem samanstanda af (E)-7-[4-(4 flúorófenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimidín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýruog lata, vaka eða hvarfefni af P450 ísóensími 3A4

Info

Publication number
IS6009A
IS6009A IS6009A IS6009A IS6009A IS 6009 A IS6009 A IS 6009A IS 6009 A IS6009 A IS 6009A IS 6009 A IS6009 A IS 6009A IS 6009 A IS6009 A IS 6009A
Authority
IS
Iceland
Prior art keywords
dihydroxyhept
isoenzyme
lazy
methylsulfonyl
pyrimidin
Prior art date
Application number
IS6009A
Other languages
English (en)
Other versions
IS2337B (is
Inventor
Raza Ali
Stuart Pears John
George Hutchinson Howard
Schneck Dennis
Babo Takahiko
Touchi Akira
Yamaguchi Yoshitaka
Original Assignee
Astrazeneca Ab
Shionogi & Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS6009(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9902593.4A external-priority patent/GB9902593D0/en
Priority claimed from GBGB9921063.5A external-priority patent/GB9921063D0/en
Priority claimed from GBGB9921064.3A external-priority patent/GB9921064D0/en
Application filed by Astrazeneca Ab, Shionogi & Co. Ltd. filed Critical Astrazeneca Ab
Publication of IS6009A publication Critical patent/IS6009A/is
Publication of IS2337B publication Critical patent/IS2337B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IS6009A 1999-02-06 2001-07-17 Lyfjasamsetning sem samanstendur af (E)-7-[4-(4 flúorófenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimidín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýru og hindra, vaka eða hvarfefni af P450 samsætuensími 3A4 IS2337B (is)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9902593.4A GB9902593D0 (en) 1999-02-06 1999-02-06 Drug combinations
GBGB9921063.5A GB9921063D0 (en) 1999-09-08 1999-09-08 Therapy
GBGB9921064.3A GB9921064D0 (en) 1999-09-08 1999-09-08 Drug combination
PCT/GB2000/000278 WO2000045817A1 (en) 1999-02-06 2000-02-01 Drug combinations comprising (e) -7 - [4 -(4 -fluorophenyl) -6 - isopropyl -2 - [methyl (methylsulfonyl) amino] pyrimidin -5 -yl] (3r,5s) -3,5 - dihydroxyhept -6 - enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4

Publications (2)

Publication Number Publication Date
IS6009A true IS6009A (is) 2001-07-17
IS2337B IS2337B (is) 2008-02-15

Family

ID=27269637

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6009A IS2337B (is) 1999-02-06 2001-07-17 Lyfjasamsetning sem samanstendur af (E)-7-[4-(4 flúorófenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimidín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýru og hindra, vaka eða hvarfefni af P450 samsætuensími 3A4

Country Status (28)

Country Link
US (3) US6982157B1 (is)
EP (1) EP1185274B1 (is)
JP (2) JP2002536331A (is)
KR (2) KR20010101790A (is)
CN (1) CN1165310C (is)
AR (1) AR029333A1 (is)
AT (1) ATE282415T1 (is)
AU (1) AU767304B2 (is)
BR (1) BR0007999A (is)
CA (1) CA2358632C (is)
CZ (1) CZ301296B6 (is)
DE (1) DE60015965T2 (is)
EE (1) EE04929B1 (is)
EG (1) EG23858A (is)
ES (1) ES2232418T3 (is)
GB (1) GB0000710D0 (is)
ID (1) ID30485A (is)
IL (1) IL144715A0 (is)
IS (1) IS2337B (is)
MX (1) MXPA01007905A (is)
MY (1) MY130606A (is)
NO (1) NO320745B1 (is)
NZ (1) NZ512982A (is)
PL (1) PL198034B1 (is)
PT (1) PT1185274E (is)
TR (1) TR200102228T2 (is)
TW (1) TWI282738B (is)
WO (1) WO2000045817A1 (is)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
ATE331512T1 (de) 2001-01-26 2006-07-15 Schering Corp Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
MEP27808A (en) 2001-01-26 2010-10-10 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
MXPA05009501A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP1606287B1 (en) 2003-03-07 2013-10-02 Merck Sharp & Dohme Corp. Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
KR20130103818A (ko) 2003-10-10 2013-09-24 벨로시스 파마슈티컬스 에이/에스 피브레이트를 포함하는 고형 제제
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
MX2007001553A (es) 2004-08-06 2008-03-07 Transform Pharmaceuticals Inc Nuevas composiciones farmaceuticas de estatina y metodos de tratamiento relacionados.
WO2007005941A2 (en) 2005-07-05 2007-01-11 President And Fellows Of Harvard College Liver targeted conjugates
EP1968593B1 (en) * 2005-12-20 2017-08-23 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
US20080109252A1 (en) * 2006-11-08 2008-05-08 Lafountain Andrea Predicting patient compliance with medical treatment
US20120130202A1 (en) * 2010-11-24 2012-05-24 Fujitsu Limited Diagnosis and Monitoring of Musculoskeletal Pathologies
AU2019285170A1 (en) * 2018-06-14 2021-01-28 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
US20220273652A1 (en) 2019-07-31 2022-09-01 Intas Pharmaceuticals Ltd. Pharmaceutical composition comprising hmg-coa reductase inhibitors and fenofibrate
WO2024223797A1 (en) 2023-04-28 2024-10-31 Institut National de la Santé et de la Recherche Médicale Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
EP0521417B1 (de) * 1991-07-02 1994-11-23 Joh. A. Benckiser GmbH Zusammenfaltbare Vorratsflasche
JP3852621B2 (ja) * 1992-01-21 2006-12-06 あすか製薬株式会社 血管内皮細胞機能改善剤
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
KR20010031501A (ko) * 1997-10-31 2001-04-16 추후제출 5-알파 환원효소 활성을 조절하는 방법 및 조성물

Also Published As

Publication number Publication date
ATE282415T1 (de) 2004-12-15
EP1185274B1 (en) 2004-11-17
NO20013811L (no) 2001-10-02
AR029333A1 (es) 2003-06-25
WO2000045817A1 (en) 2000-08-10
US20060040969A1 (en) 2006-02-23
DE60015965T2 (de) 2006-01-05
JP2002536331A (ja) 2002-10-29
ES2232418T3 (es) 2005-06-01
CA2358632A1 (en) 2000-08-10
EE04929B1 (et) 2007-12-17
US20090042911A1 (en) 2009-02-12
US6982157B1 (en) 2006-01-03
IL144715A0 (en) 2002-06-30
JP2007277267A (ja) 2007-10-25
AU767304B2 (en) 2003-11-06
CZ301296B6 (cs) 2010-01-06
NZ512982A (en) 2003-08-29
MXPA01007905A (es) 2003-06-04
DE60015965D1 (de) 2004-12-23
KR20010101790A (ko) 2001-11-14
PL364780A1 (en) 2004-12-13
AU2121800A (en) 2000-08-25
CN1338936A (zh) 2002-03-06
HK1041817A1 (en) 2002-07-26
TR200102228T2 (tr) 2002-03-21
CA2358632C (en) 2008-10-28
CN1165310C (zh) 2004-09-08
IS2337B (is) 2008-02-15
EE200100406A (et) 2002-10-15
MY130606A (en) 2007-07-31
NO320745B1 (no) 2006-01-23
BR0007999A (pt) 2001-11-06
EP1185274A1 (en) 2002-03-13
PL198034B1 (pl) 2008-05-30
ID30485A (id) 2001-12-13
PT1185274E (pt) 2005-03-31
EG23858A (en) 2007-11-18
KR20060117381A (ko) 2006-11-16
CZ20012844A3 (cs) 2001-11-14
NO20013811D0 (no) 2001-08-03
TWI282738B (en) 2007-06-21
GB0000710D0 (en) 2000-03-08

Similar Documents

Publication Publication Date Title
IS6009A (is) Lyfjablöndur sem samanstanda af (E)-7-[4-(4 flúorófenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimidín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýruog lata, vaka eða hvarfefni af P450 ísóensími 3A4
IS2820B (is) Samsettar samsetningar sem ná yfir (E)-7-[4-(4-flúorofenýl)-6-ísóprópyl-2-[metýl(metýlsúlfónýl)-amínó]pýrimídín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýru
ZA200205331B (en) Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid.
IL175086A0 (en) Process for the manufacture of the calcium salt of rosuvastatin (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl) amino]pyrimidin-5-yl] 3r,5s)- 3,5-dihydroxyhept-6-enoic acid and crystalline intermediates thereof
EE200100430A (et) Tert-butüül-(E)-(6-[2-[4-(4-fluorofenüül)-6-isopropüül-2-[metüül(metüülsulfonüül)amino]pürimidiin-5-üül]vinüül](4R,6S)-2,2-dimetüül[1,3]dioksaan-4-üül)atsetaadi valmistamismeetod
CA2313783A1 (en) Pharmaceutical compositions of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid or a salt thereof
HUP0104828A3 (en) Crystalline bis[(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl-(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-1,5-dihydroxyhept-6-enoic acid]calcium salt, pharmaceutical composition containing it and process for its preparation
TWI370817B (en) Novel crystalline form of bis[(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[ methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt,and relevant manufacture process, pharmaceutical composition, and use
CA2429263A1 (en) Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia
DE50213202D1 (de) Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
HUP0104977A3 (en) Drug combinations comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl-(methylsulfonyl)-amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4
SI1185274T1 (en) Drug combinations comprising (e)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(methylsulfonyl)amino)pyrimidin-5-yl)(3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4
DK1185274T3 (da) Lægemiddelkombinationer omfattende (E) - 7 -[4- (4-fluorphenyl) - 6 - isopropyl-2 [methyl(methylsulfonyl)amino ]-pyrimidin-5-yl] (3R,5S) - 3,5-dihydroxyhept-6-ensyre og en inhibitor af, en inducer af eller et substrat for P450 isoenzym 3A4